Products Affected - Description

• • Valcyte oral powder for solution, Genentech, 50 mg/mL, 100 mL glass bottle, NDC 00004-0039-09
  • Valcyte oral tablet, Genentech, 450 mg, bottle, 60 count, NDC 00004-0038-86
  • Valganciclovir hydrochloride oral tablet, Camber, 450 mg, bottle, 60 count, NDC 31722-0832-60
  • Valganciclovir hydrochloride oral tablet, Cipla USA, 450 mg, bottle, 60 count, NDC 69097-0277-03 - discontinued
  • Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 20 count, NDC 00904-6796-10
  • Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 30 count, NDC 00904-6796-04
  • Valganciclovir hydrochloride oral powder for solution, Teva, 50 mg/mL, 100 mL glass bottle, NDC 00591-2579-20

Reason for the Shortage

• • Ajanta was not available to provide information.
  • Camber did not provide a reason for the shortage.
  • Cipla discontinued valganciclovir tablets.
  • Dr. Reddy's was not available to provide information.
  • Genentech is transferring valganciclovir presentations to H2 Pharma.
  • Major has valganciclovir tablets available.
  • Somerset has valganciclovir powder for solution available.
  • Teva did not provide a reason for the shortage.

Available Products

• • Valganciclovir hydrochloride oral powder for solution, Somerset Therapeutics LLC, 50 mg/mL, 100 mL glass bottle, NDC 70069-0810-01

• • Camber has valganciclovir 450 mg tablets in 60 count bottles on back order and the company estimates a release date of mid-May 2023. They will be allocating product upon release.
  • Genentech has valganciclovir 450 mg tablets and 50 mg/mL oral solution available in limited quantities.
  • Major has valganciclovir 450 mg tablets in 20-count unit-dose packs and 30-count unit-dose packs on back order and the company cannot estimate a release date.
  • Teva has valganciclovir 50 mg/mL powder for solution in 100 mL bottles on back order and the company estimates a release date in late-June 2023.